CMPS (COMPASS Pathways) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The share price retrospective for COMPASS Pathways plc (CMPS) demonstrates an EV/EBITDA of 0.00. High barriers to entry are driven by costly research and patent protection of chemical compounds, which complicates market access for new players. The business relies on the optimization of cross-border supplies for clinics, while future revenues depend on the agreement of psilocybin-based therapy pricing with government regulators.

CMPS (COMPASS Pathways PLC) Company Value to EBITDA history from 11/23/2025 to 11/10/2026

Comprehensive metric breakdowns and analytics for compasspathways.com (CMPS)

- market price and analyst price targets:

Price Chart Compass Pathways|CMPS - Forecast Levels Chart

- business market valuation indicators:

Market Value COMPASS Corp|CMPS - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share COMPASS Pathways|CMPS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio compasspathways.com|CMPS - Cumulative Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

CMPS - Net Income|Expected Profit COMPASS Pathways plc|CMPS - Market Cap to Net Income|Forward P/E Multiple COMPASS Pathways plc|CMPS - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COMPASS Corp|CMPS - Operating income before deduction of amortization|Earnings per share for the last twelve months COMPASS Pathways|CMPS - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months compasspathways.com|CMPS - Earnings per share increase in current year|Net earnings per share growth forecast for next year COMPASS Pathways plc

Initial company analysis:Compass Pathways CMPS

COMPASS Pathways plc (CMPS) invests in scientific collaborations with psychopharmacology institutes to develop breakthrough therapies. These expenditures impact operating profit, which the metric compares against the total enterprise value, including debt. This indicator measures the payback period of assets by neutralizing the impact of tax regimes and credit loads. By analyzing the trend of the core EV/EBITDA multiple, an investor determines the real value of COMPASS Pathways plc (CMPS) relative to its ability to generate cash flow.

Competitors of COMPASS Pathways plc (CMPS)

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ghres.com GHRS|MNMD (MindMed) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA LB Pharmaceuticals, Inc. (LBRX)|DRUG (Bright Minds Biosciences Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Vanda (VNDA)|EV/EBITDA Multiple CYBN|ANRO (altoneuroscience.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRx Pharmaceuticals, Inc. NRXP|Cingulate Inc (CING) - Company Value to EBITDA|Silo Pharma - EV/EBITDA Multiple|China Pharma Holdings (CPHI) - Enterprise Value to EBITDA Ratio|Clearmind Medicine Inc. (CMND) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA pacificbayminerals.com (PBM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SciSparc|Enterprise Value to EBITDA Ratio Seelos Therapeutics Inc. (SEEL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virpax Pharmaceuticals (VRPX)|KRTX: Company Value to Operating Income Before Depreciation Ratio